Hidradenitis Suppurativa (HS) Clinical Trials

17 recruiting

Hidradenitis Suppurativa (HS) Trials at a Glance

17 actively recruiting trials for hidradenitis suppurativa (hs) are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Phoenix, Boston, and Tampa. Lead sponsors running hidradenitis suppurativa (hs) studies include Incyte Corporation, Peking Union Medical College, and Citryll BV.

Browse hidradenitis suppurativa (hs) trials by phase

Treatments under study

About Hidradenitis Suppurativa (HS) Clinical Trials

Looking for clinical trials for Hidradenitis Suppurativa (HS)? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hidradenitis Suppurativa (HS) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hidradenitis Suppurativa (HS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 2

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Sinocelltech Ltd.60 enrolled1 locationNCT07244510
Recruiting

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Rheumatoid Arthritis (RA)Hidradenitis Suppurativa (HS)
Sonoma Biotherapeutics, Inc.36 enrolled10 locationsNCT07123038
Recruiting
Phase 3

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled316 locationsNCT06855498
Recruiting
Phase 2

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Incyte Corporation40 enrolled27 locationsNCT07213973
Recruiting
Phase 2Phase 3

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Bluefin Biomedicine, Inc.210 enrolled33 locationsNCT07287644
Recruiting
Phase 2

A Study With CIT-013 in HS Patients

Hidradenitis Suppurativa (HS)
Citryll BV96 enrolled24 locationsNCT06993233
Recruiting
Phase 2

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Hidradenitis Suppurativa (HS)
Zura Bio Inc225 enrolled56 locationsNCT06993610
Recruiting
Phase 2

The Safety and Efficacy of Roflumilast Foam in HS

Hidradenitis Suppurativa (HS)
Beth Israel Deaconess Medical Center20 enrolled1 locationNCT07263230
Recruiting
Phase 2

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Navigator Medicines, Inc.150 enrolled10 locationsNCT07384975
Recruiting
Not Applicable

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

Hidradenitis Suppurativa (HS)
Rutgers, The State University of New Jersey10 enrolled1 locationNCT07316192
Recruiting

Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Hidradenitis Suppurativa (HS)
Novartis Pharmaceuticals77 enrolled4 locationsNCT06785779
Recruiting
Phase 1

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

Hidradenitis Suppurativa (HS)
Wynn Medical Center30 enrolled1 locationNCT07155239
Recruiting

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

Chronic Spontaneous Urticaria (CSU)Hidradenitis Suppurativa (HS)Psoriasis (PsO)+2 more
Leiden University Medical Center840 enrolled8 locationsNCT07021495
Recruiting

Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Peking Union Medical College50 enrolled1 locationNCT07109765
Recruiting
Phase 1

A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients

Atopic DermatitisRheumatoid Arthritis (RA)Hidradenitis Suppurativa (HS)
Shanghai Qilu Pharmaceutical Research and Development Center LTD102 enrolled1 locationNCT06946641
Recruiting

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)SecukinumabHidradenitis Suppurativa (Acne Inversa)
Peking Union Medical College100 enrolled1 locationNCT06926192
Recruiting
Early Phase 1

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

Hidradenitis Suppurativa (HS)
Virginia Clinical Research, Inc.15 enrolled1 locationNCT06645821